Sponsor Pipeline

Lomond Therapeutics Holdings, Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
3
Active Trials
2
Recruiting
3
Disease Areas
5
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-01 NCT06708897
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies		 Primary endpoint(s) modified
2026-08-01 NCT06708897
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies		 Enrollment increased: 66 -> 84 participants
2026-08-01 NCT06708897
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies		 Trial arms changed: 8 -> 12
2026-08-01 NCT06708897
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies		 date change Primary completion pushed: 2026-03 -> 2028-01
2026-08-01 NCT06708897
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies		 date change Completion pushed: 2028-04 -> 2028-07
Active Trials by Phase
Phase 1
3
Active Trials
NCT IDTitleConditionStatus
Phase 1
NCT06366789 Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of… AML With Gene Mutations Recruiting
NCT06708897 A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies CLL / SLL Recruiting
NCT07303660 A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients Acute Myeloid Leukemia Not Yet Recruiting
Disease Areas
Acute Myeloid Leukemia (AML) (2) Leukemia (2) Chronic Lymphocytic Leukemia (CLL) (1)
Get alerts when Lomond Therapeutics Holdings, Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free